Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + apatinib with or without cytoreductive surgery in metastatic renal cell carcinoma
ChiCTR2100044154Phase 2Recruiting
- Sponsor
- Peking University First Hospital
- Start
- Mar 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of camrelizumab and Rivoceranib in renal cell carcinoma (RCC) and clear cell renal cell carcinoma (ccRCC) (2 arms), sponsored by Peking University First Hospital. Primary endpoints: Blood routine, Urine routine and 5 more. Started Mar 2021; status: recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
renal cell carcinoma (RCC)clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on ChiCTR2100044154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100044154.